RadNet (RDNT) Expected to Announce Quarterly Earnings on Sunday

Key Points

• RadNet will likely report Q1 2026 results after the market close on May 10, 2026, with the earnings call set for May 11 at 10:30 AM ET; analysts expect a loss of ($0.14) EPS on revenue of $557.97 million.
• In the prior quarter RadNet beat estimates with $0.23 EPS and $547.71 million in revenue (up 14.8% YoY), and analysts forecast about $1 EPS for the current and next fiscal years.
• The stock trades near $56.85 with a $4.45 billion market cap and a consensus rating of "Moderate Buy" (consensus target $88.14); insiders recently sold shares and institutional investors own roughly 77.9% of the company.

RadNet (NASDAQ:RDNT - Get Free Report) will likely be issuing its Q1 2026 results after the market closes on Sunday, May 10th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $557.97 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 10:30 AM ET.

RadNet (NASDAQ:RDNT - Get Free Report) last issued its quarterly earnings data on Monday, March 2nd. The medical research company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.04. RadNet had a positive return on equity of 2.52% and a negative net margin of 0.91%.The business had revenue of $547.71 million for the quarter, compared to the consensus estimate of $515.67 million. During the same period last year, the business earned $0.22 EPS. The firm's revenue was up 14.8% compared to the same quarter last year. On average, analysts expect RadNet to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

RadNet Stock Up 0.5%

Shares of RDNT stock opened at $56.85 on Friday. The stock's 50 day simple moving average is $60.89 and its 200 day simple moving average is $70.23. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.76 and a current ratio of 1.76. RadNet has a twelve month low of $50.76 and a twelve month high of $85.84. The company has a market capitalization of $4.45 billion, a price-to-earnings ratio of -227.40 and a beta of 1.44.

Wall Street Analyst Weigh In

RDNT has been the topic of a number of recent analyst reports. UBS Group set a $92.00 price objective on RadNet in a research note on Friday, January 9th. KeyCorp raised RadNet to a "strong-buy" rating in a research note on Friday, January 9th. Jefferies Financial Group reissued a "buy" rating and issued a $91.00 price objective on shares of RadNet in a research note on Tuesday, March 3rd. Finally, Barclays cut their price objective on RadNet from $86.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $88.14.

Insider Transactions at RadNet

In other RadNet news, insider Alma Gregory Sorensen sold 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $62.15, for a total value of $932,250.00. Following the sale, the insider owned 1,208,923 shares of the company's stock, valued at $75,134,564.45. This trade represents a 1.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.60% of the stock is owned by company insiders.

Institutional Trading of RadNet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. RTW Investments LP grew its holdings in RadNet by 39.9% in the 4th quarter. RTW Investments LP now owns 3,938,500 shares of the medical research company's stock valued at $281,012,000 after buying an additional 1,122,956 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in RadNet by 30.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,699,082 shares of the medical research company's stock valued at $192,581,000 after buying an additional 627,936 shares during the last quarter. State Street Corp grew its holdings in RadNet by 1.6% in the 4th quarter. State Street Corp now owns 2,579,073 shares of the medical research company's stock valued at $184,017,000 after buying an additional 41,356 shares during the last quarter. Invesco Ltd. grew its holdings in RadNet by 26.4% in the 4th quarter. Invesco Ltd. now owns 1,596,780 shares of the medical research company's stock valued at $113,930,000 after buying an additional 333,911 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in RadNet by 1.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,413,734 shares of the medical research company's stock valued at $107,741,000 after buying an additional 19,182 shares during the last quarter. Institutional investors and hedge funds own 77.90% of the company's stock.

About RadNet

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.